These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 28333373

  • 1. Ventricular arrhythmias in patients with newly diagnosed nonischemic cardiomyopathy: Insights from the PROLONG study.
    Duncker D, König T, Hohmann S, Bauersachs J, Veltmann C.
    Clin Cardiol; 2017 Aug; 40(8):586-590. PubMed ID: 28333373
    [Abstract] [Full Text] [Related]

  • 2. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S, Rosenkaimer SL, Hohneck A, Lang S, El-Battrawy I, Rudic B, Tülümen E, Stach K, Kuschyk J, Akin I, Borggrefe M.
    BMC Cardiovasc Disord; 2018 Mar 15; 18(1):52. PubMed ID: 29544442
    [Abstract] [Full Text] [Related]

  • 3. Utility of the Wearable Cardioverter-Defibrillator in Patients With Newly Diagnosed Cardiomyopathy: A Decade-Long Single-Center Experience.
    Singh M, Wang NC, Jain S, Voigt AH, Saba S, Adelstein EC.
    J Am Coll Cardiol; 2015 Dec 15; 66(23):2607-2613. PubMed ID: 26670060
    [Abstract] [Full Text] [Related]

  • 4. Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study.
    Duncker D, König T, Hohmann S, Bauersachs J, Veltmann C.
    J Am Heart Assoc; 2017 Jan 17; 6(1):. PubMed ID: 28096098
    [Abstract] [Full Text] [Related]

  • 5. Comparison of ventricular tachyarrhythmia characteristics in patients with idiopathic dilated or ischemic cardiomyopathy and defibrillators implanted for primary prevention.
    Streitner F, Kuschyk J, Dietrich C, Mahl E, Streitner I, Doesch C, Veltmann C, Schimpf R, Wolpert C, Borggrefe M.
    Clin Cardiol; 2011 Oct 17; 34(10):604-9. PubMed ID: 21887690
    [Abstract] [Full Text] [Related]

  • 6. Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator.
    Duncker D, Haghikia A, König T, Hohmann S, Gutleben KJ, Westenfeld R, Oswald H, Klein H, Bauersachs J, Hilfiker-Kleiner D, Veltmann C.
    Eur J Heart Fail; 2014 Dec 17; 16(12):1331-6. PubMed ID: 25371320
    [Abstract] [Full Text] [Related]

  • 7. Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator.
    Daimee UA, Vermilye K, Moss AJ, Goldenberg I, Klein HU, McNitt S, Zareba W, Kutyifa V.
    Heart Rhythm; 2018 Sep 17; 15(9):1379-1386. PubMed ID: 29678779
    [Abstract] [Full Text] [Related]

  • 8. Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis.
    Duncker D, Westenfeld R, Konrad T, Pfeffer T, Correia de Freitas CA, Pfister R, Thomas D, Fürnkranz A, Andrié RP, Napp A, Schmitt J, Karolyi L, Wakili R, Hilfiker-Kleiner D, Bauersachs J, Veltmann C.
    Clin Res Cardiol; 2017 Aug 17; 106(8):582-589. PubMed ID: 28275862
    [Abstract] [Full Text] [Related]

  • 9. Wearable Cardioverter-Defibrillators following Cardiac Surgery-A Single-Center Experience.
    Heimeshoff J, Merz C, Ricklefs M, Kirchhoff F, Haverich A, Bara C, Kühn C.
    Thorac Cardiovasc Surg; 2019 Mar 17; 67(2):92-97. PubMed ID: 29925094
    [Abstract] [Full Text] [Related]

  • 10. The Wearable Cardioverter Defibrillator in Nonischemic Cardiomyopathy: A US National Database Analysis.
    Salehi N, Nasiri M, Bianco NR, Opreanu M, Singh V, Satija V, Jhand AS, Karapetyan L, Safadi AR, Surapaneni P, Thakur RK.
    Can J Cardiol; 2016 Oct 17; 32(10):1247.e1-1247.e6. PubMed ID: 26975224
    [Abstract] [Full Text] [Related]

  • 11. Absence of left bundle branch block and blood urea nitrogen predict improvement in left ventricular ejection fraction in patients with cardiomyopathy and wearable cardioverter defibrillators.
    Mehta NA, Abdulsalam N, Kouides R, Ahmed H, Atif R, Shah A, Taylor S, Chuprun D, Huang D, Rao M.
    Clin Cardiol; 2020 Mar 17; 43(3):260-266. PubMed ID: 31860745
    [Abstract] [Full Text] [Related]

  • 12. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry).
    Kutyifa V, Moss AJ, Klein H, Biton Y, McNitt S, MacKecknie B, Zareba W, Goldenberg I.
    Circulation; 2015 Oct 27; 132(17):1613-9. PubMed ID: 26316618
    [Abstract] [Full Text] [Related]

  • 13. Outcomes during and after the use of the wearable cardioverter-defibrillator in a tertiary-care and a regional hospital in Switzerland.
    Kovacs B, Reek S, Saguner AM, Krasniqi N, Eriksson U, Duru F.
    Swiss Med Wkly; 2019 Nov 04; 149():w20136. PubMed ID: 31707723
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
    Yazaki K, Suzuki A, Shiga T, Minami Y, Arai K, Ashihara K, Shoda M, Hagiwara N.
    BMC Cardiovasc Disord; 2021 Feb 19; 21(1):106. PubMed ID: 33607967
    [Abstract] [Full Text] [Related]

  • 16. The US Experience of the Wearable Cardioverter-Defibrillator in Pediatric Patients.
    Spar DS, Bianco NR, Knilans TK, Czosek RJ, Anderson JB.
    Circ Arrhythm Electrophysiol; 2018 Jul 19; 11(7):e006163. PubMed ID: 29945928
    [Abstract] [Full Text] [Related]

  • 17. Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator.
    Skowasch D, Ringquist S, Nickenig G, Andrié R.
    PLoS One; 2018 Jul 19; 13(3):e0194496. PubMed ID: 29566033
    [Abstract] [Full Text] [Related]

  • 18. Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death.
    Kutyifa V, Vermilye K, Daimee UA, McNitt S, Klein H, Moss AJ.
    Europace; 2018 Sep 01; 20(FI2):f225-f232. PubMed ID: 29905788
    [Abstract] [Full Text] [Related]

  • 19. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction.
    Epstein AE, Abraham WT, Bianco NR, Kern KB, Mirro M, Rao SV, Rhee EK, Solomon SD, Szymkiewicz SJ.
    J Am Coll Cardiol; 2013 Nov 19; 62(21):2000-2007. PubMed ID: 23916930
    [Abstract] [Full Text] [Related]

  • 20. Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: A national database analysis.
    Opreanu M, Wan C, Singh V, Salehi N, Ahmad J, Szymkiewicz SJ, Thakur RK.
    J Heart Lung Transplant; 2015 Oct 19; 34(10):1305-9. PubMed ID: 26094085
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.